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Abstract
Hippocrates was the first to raise awareness of medicine as a science. He asserted the 
body being a unified whole and emphasized the importance of preventive and predictive 
medicine, spurring physicians to foster patient collaboration. Recent achievements today 
have permitted a new approach “P4 medicine” – Predictive, Preventive, Personalized 
and Participatory – with the aim of depicting an individual’s health history and molecular 
profile in determining the best medical intervention in maintaining or restoring wellbe-
ing. There is a link, which brings together Hippocrates and P4 Medicine. This review 
will elaborate further this statement, considering the scientific achievements that paved 
the way for recent medical approaches. Emphasis will be given to the social impact of 
new diagnostic and therapeutic protocols, considering their costs and their success prob-
abilities.
INTRODUCTION
Hippocrates was the first to assert that diseases are 
derived from natural causes and raised the awareness 
of medicine being a science and underlined its his-
torical development [1-5]. The Greek scientist consid-
ered medicine a union between theory and practice, 
and stated “Medicine had already fulfilled important 
achievements, and acquired all the premises for going 
further, always considering the discoveries already done 
and moving from them”. 
Since Hippocrates, medical sciences have come down 
a long path to the present day sequencing of the com-
plete human genome, as defined by the scientist F.S. 
Collins, a revolution in the biomedical sciences, “Gene 
isolation provides the best hope for understanding hu-
man disease at its most fundamental level… Knowledge 
about genetic control of cellular functions will underpin 
future strategies to prevent or treat disease phenotypes” 
[6-9].
The astounding project of human genome sequenc-
ing would not have been possible without past scientific 
discoveries, such as the Mendel’s laws and their appli-
cation in the analysis of human inborn errors of me-
tabolism, as investigated by Garrod, the elucidation of 
the double-helical structure of DNA, the genetic code, 
and the implementation of recombinant DNA technol-
ogy [7]. In the future, the analysis and characterization 
of human sequences and the cross-referencing of spe-
cies may make it possible to understand the biological 
structure and function of many genes and to construct 
cellular pathways in healthy and diseased cells. Collins 
foresaw “obtaining the sequence of the human genome 
is the end of the beginning” [8, 10, 11].
The past and the future of the Human Genome Proj-
ect confirm that biomedical research is like a long chain, 
and each link represents a new achievement connected 
to the previous one, just as Hippocrates had suggested 
“going further, always considering the discoveries al-
ready done and moving from them” [6-10].
In the post genomic era1, the accomplishment of the 
Human Genome Project and the modern “omics” tech-
nologies are providing new directions in medical ap-
proaches, and P4 Medicine appears to be the acme of 
the new perspectives [12-14], aiming to redefine medi-
cal intervention. As defined by the Predictive, Preven-
tive, Personalized “Ps”, medical interventions must be 
tailored considering the medical, genetic and personal 
data of each individual [15-17]. While, the Participa-
tory “P” hopes and calls for the active involvement of 
patients [18]. These perspectives of P4 Medicine recall 
Hippocrates’ thoughts “the human body as one unified 
organism to be considered as one coherent and inte-
grated whole, and the disease symptoms should be ana-
lyzed and evaluated considering the environment and 
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1The term “the post genomic era” highlights the current period of time 
that follows the Human Genome Project achievement. The same pe-
riod of time can be also identified with the term “genomic era”. We 
have selected and used the term “post genomic era” to clearly underline 
the Human Genome Project accomplishment, and the start of a new 
scientific era committed to characterize genes’ functions, regulation 
and interactions. 
























social status of the patients”, and “the best physician is 
the one who can prevent and predict” [1-5]. 
The medical sciences have come down a long path 
from Hippocrates; still, his recommendations for pur-
suing a correct and suitable therapeutic regime now 
appear in the post genomic approach of 4P Medicine. 
P4 MEDICINE
The achievements of the Human Genome Project and 
“omics” technologies have given new impetus to Science 
[6-10]. Today, the information derived from this project 
can be considered akin to a huge book that is to be wise-
ly read and interpreted to unravel the genes structure 
and hierarchy, this being the principal goal of the post 
genomic era [8]. This achievement will not be simple 
to attain. Researchers of diverse disciplines have come 
together with their expertise in the effort to pursue and 
reach this compelling result that, in the end, will permit 
the understanding of the mechanisms underlying the 
regulation or deregulation of disease-associated genes. 
Biologists, mathematicians, chemists and engineers are 
all collaborating to set up new protocols and instru-
ments dedicated in performing a wide range analysis 
of DNA, RNA and proteins with even the use of com-
pelling methods [13, 19]. An example, the evolution of 
instruments for synthesizing, detecting, and sequencing 
DNA has permitted the reading of a human genome in a 
short time and at a reasonable cost, making the analysis 
of polymorphisms and gene alterations more and more 
viable. Nowadays, it is possible to sequence the whole 
human genome in about three days, and for less than € 
3000. However, the new technologies are improving at a 
fast rate, shortening the sequencing time and the costs 
becoming more affordable each day [19]. RNA and pro-
tein Microarrays are providing suitable information to 
decipher the molecular mechanisms of gene transcrip-
tions and translation [20, 21]. Moreover, mathemati-
cians are contributing to the post genomic challenges 
by developing modern computational tools capable of 
analyzing a multitude of data acquired via these new 
sophisticated protocols [22]. The new “omics” techno-
sciences, such as genomics, proteomics, metabolomics 
and interactomics, have the objective to interpret and 
organize this huge amount of results, to ultimately de-
sign molecular networks and pathways. In the future, 
these “omics” profiles may be used as tools for the better 
prevention, diagnosis, and treatment of diseases. In fact, 
the molecular data will be a determinant in improving 
diagnostic and therapeutic strategies when personal and 
life style information is considered [23].
Besides this, the new platforms of communication 
are revolutionizing the access to medical information 
for patients and their families, favoring their active par-
ticipation in decision making of their own health, aided 
by the Internet [24].
More than a decade ago, Leroy Hood explored all 
these potentialities and proposed the Predictive, Pre-
ventive, Personalized and Participatory medicine, 
known today as P4 Medicine. Leroy Hood put forward 
this concept with the objective of changing medical in-
tervention from the care of the diseases to the mainte-
nance of wellbeing [25-27].
This approach aspires to define and explore healthy 
and altered molecular profiles to predict the health 
course of individuals, considering their unique genetic 
and epigenetic background embedded in their specific 
social and physical environments.
The molecular parameters, integrated with the medi-
cal histories of patients and their health outcomes de-
rived from the common clinical observations, will give 
some insight into disease outcomes and how these af-
fect the physiological status of the individual.
Combining the molecular, clinical and personal data 
together, it would be possible to define genetic variants 
along with molecular pathways related to status of well-
ness and sickness. This could highlight the potential 
alterations correlated in disease onset. The dynamics 
of perturbed molecular profiles will potentially predict 
the emergence of illness; therefore, it may help to select 
personalized interventions directed to prevent or even-
tually cure diseases and to restore the wellness status. 
These interventions will focus on both suitable drugs 
and appropriate life style changes [26-28].
An extensive implementation of “omics” techno-
sciences and of computational tools is fundamental in 
collecting and assembling the appropriate data, but it is 
not enough. Even though the P4 approach is based on 
the analysis of molecular, phenotypic and lifestyle data 
of each individual, this personal data will be correctly 
interpreted only if collected by benchmark procedures 
and compared with similar data of other patients [26-
28]. Comparative studies will define the best methods 
of sample preparation and the most suitable algorithms 
to design unbiased molecular patterns. Finally, these 
comparisons will highlight the molecular variations 
that are relevant in maintaining or losing the well-being 
status. This selection and discernment of the relevant 
data will clearly define the health molecular networks of 
each individual, and by scoring their fluctuation it will 
be possible to predict illness outcome and to plan pre-
vention strategies or therapeutic interventions. These 
comparative studies require a broad access to personal 
datasets of patients and the creation of linkages among 
these. Hence, scientists are faced with the challenge of 
acquiring, sharing, protecting these data, together with 
all the resulting ethical problems, such as storage and 
management, encouraging patients to give access to 
their personal and medical information. Additionally, 
physicians and other members of the medical commu-
nity should master how to share their information, sci-
entific knowledge and objectives with patients [29, 30]. 
Patients must be made aware that their, clinical, mo-
lecular, phenotypic data and life-style are fundamental 
for the advancement of knowledge, as this will increase 
their willingness to provide access to their personal 
data. In fact, this conscious patient participation is the 
purpose of the Participatory “P” and is mandatory in 
moving toward the P4 approach; however, there is the 
likelihood that this will be the hardest goal to achieve.
P4 MEDICINE VERSUS HIPPOCRATES 
The scientist Leroy Hood has launched P4 Medicine 
in exploring and exploiting the knowledge and tech-
nologies derived from the Human Genome Project. 
























He has introduced the P4 approach with the intent to 
potentiate prevention as the main component of medi-
cal care. The scientist explains that the “omics” mo-
lecular data and the new computational tools can favor 
and support this concept, shifting medical intervention 
from the care of the diseases to the maintenance of 
wellbeing [16]. 
Although P4 Medicine appears to be a modern sci-
ence taking into consideration the knowledge and the 
“omics” technologies, of which it is based on. Reviewing 
this in depth, one perceives that its premises and pur-
poses actually echo the thoughts of the ancient Greek 
physicist Hippocrates.
Hippocrates had been the first to deny that diseases 
were derived from the curse of the gods and introduced 
the concept of medicine as science. Indeed, he empha-
sized “Medicine has acquired all the premises for going 
further, always considering the discoveries already done 
and moving from them”. For these reasons, Hippocrates 
is claimed to be the “father of medicine”, and this sou-
briquet acquires even more relevance when comparing 
his ideas with the P4 Medicine approach [3, 31].
In fact, the Greek physician founded his method on 
the concept that the human body functioned as one 
unified organism, a coherent and integrated whole, 
embedded in its own physical and social environment. 
Hippocrates believed in the continuity between health 
and disease. He perceived diseases as a succession of 
regulated phenomena that were bonded together and 
advised “diseases never affect only one part of the body, 
they affect the health balance of all body”. Additionally, 
Hippocrates encouraged physicians to analyse symp-
toms to interpret the present trends of the disease and 
to predict its development relative to the past health 
history of the patient. His approach intends to examine 
and analyse the present and past health conditions to 
focus on their possible future development. In this re-
gard, the ancient scientist stressed “He who administers 
therapy must first know the whole man as a unique psy-
chosomatic entity in relation to his social and natural 
environment” [1-5].
The Greek physician pointed out the importance of 
geography, climate and hydrological environment as 
main determinants that, besides nutrition and hygiene, 
could condition the onset of diseases and their devel-
opment. He underlined that the social environment, as 
well as working and living conditions may influence the 
psychology and personal feeling relative to the illness, 
and may have a significant relevance for the disease 
outcome and development. In this respect, Hippocrates 
proclaimed “The best physician is who can prevent and 
predict diseases”, and spurred his pupils to achieve this 
objective by investigating “the entire patient and his en-
vironment” [5, 31].
Marketos had clearly explained “He observed dis-
eases with the eye of a naturalist and established rules 
by which the physician would know what to expect and 
what to do at the right time. Every patient was a sepa-
rate case and this individuality precludes a fixed dogma 
for curative methods. Hippocrates and his disciples col-
lected scientific case histories as no-one had done previ-
ously; for example in Epidemics he described the events 
of illness with cool detachment and in a truly scientific 
way he declared: State the past, diagnose the present and 
foretell the future” [3, 4]. According to Hippocrates, the 
past and the present can provide the proper knowledge 
to prognosticate the future, thought that brought a rev-
olution in Medicine and all Sciences [2]. Hence, Hip-
pocrates’ ideals of good medical practice relied on the 
holistic view of the human body, examined relative to 
the past and present health history and life style of every 
individual, to better prevent, predict and cure illnesses.
This can be said to be true, as the thoughts of the 
ancient scientist parallel the premises of the P4 Medi-
cine of today, in aiming to protect the wellness status of 
individuals by analysing and comparing their personal 
and clinical data. 
P4 Medicine exploits two thousand years of scien-
tific achievements and the latest molecular and com-
putational achievements (Table 1) [15]; however, the 
fundaments still echo Hippocrates’ idea of a medicine 
founded on the examination of the patients as one 
whole taking into account their physical, social and 
psychological status. This statement is even more valid 
when considering the role of patients along the thera-
peutic path.
Hippocrates strongly advised physicians to focus their 
attention on the patient as well as on the disease, stress-
ing the importance of the relationship between physi-
cian and patient. According to Hippocrates, the Art of 
medicine has three Actors, the disease, the patient and 
the physician; the physician is the “Art Master”, and 
should fight the diseases together with the patient. The 
Greek scientist encouraged the physician to provide the 
patient the education for the healing process, helping 
the patient to understand oneself and the disease, mak-
ing the patient a protagonist in fighting the disease [1-
5]. Furthermore, in his first aphorism “Life is short, and 
Art is long”, Hippocrates highlights the brevity of hu-
man life and the improbability for physicians to acquire 
all the necessary knowledge about any disease they may 
encounter. The Greek scientist warned physicians to be 
aware when treating diseases that they may not always 
have adequate and appropriate expertise in achieving 
a correct diagnosis and cure. To overcome this disad-
vantage, Hippocrates advised medical practitioners to 
harvest information from their patients and other stake-
holders which would fill the knowledge voids and pre-
vent other failures [5, 32]. In reality, this aphorism gave 
rise to Participatory medicine long before the advent of 
P4 Medicine [18].
Even if at first sight, Hippocrates, P4 medicine and 
the Human Genome Project appear as far apart as 
the years that separate them, they are intrinsically tied 
when considering the ancient reasoning and the ratio-
nale behind the modern scientific achievements and 
their future perspectives [1-5, 18]. Furthermore, the 
will to educate the patient about his disease to foster 
his active collaboration to combat the illness brings the 
ancient scientist and the modern approach that much 
closer. Hippocrates and Leroy Hood both hoped for a 
proactive medicine mainly directed in predicting and 
preventing illness more than curing it, and underlines 
the crucial role of an informed and collaborative pa-
























tient. The physicians must create a deep collaborative 
relationship with patients and give them clear and ad-
equate information about their health status, since a 
more participative patient will contribute positively to 
the therapeutic path. A good relationship will facilitate 
the exchange and comprehension of medical informa-
tion, will permit a better identification of the patient 
needs, and will help to contain patient fears. A good 
communication will encourage the patient to share 
more personal and illness information, and therefore it 
may allow a better and faster diagnosis, thus playing 
unarguably a more positive role in health care decisions.
P4 MEDICINE ETHICAL, SOCIAL  
AND ECONOMIC IMPLICATIONS  
AND HIPPOCRATES 
P4 Medicine is still far from being accomplished, as 
it already poses several issues that need to be addressed 
Table 1
Relevant molecular biology achievements from ’800 up to the Human Genome Project
Year Main achievements Scientists
1865 Hybridization of pea plants G. Mendel
1869 Localization of DNA in the nucleus and named “nucleic acid” F. Miescher
1885 Hypothesizing of chromosomes as the inheritance carriers W. Roux
1902 Formulation of heredity chromosomal theory W. Sutton
1914 Localization of genes on chromosomes T. Morgan
C. Bridges
1944 Hypothesis of genes being made up of DNA O. Avery
C. Mcleod
M. McCarty
1944 The book What is life? suggesting complex molecules as carriers of  genetic code for living organisms E. Schrödinger
1953 The proposing of double-stranded, helical, complementary, anti-parallel model for DNA J. Watson 
F. Crick
1959 Discovered of “operon” F. Jacob 
J. Monod
1961 Determination of  “genetic code” M. Nirenberg
H. Mathaei
S. Ochoa
1961 Discovery of messenger RNA S. Brenner
F. Jacob
M. Meselson
1966 Finalization of genetic code M. Nirenberg
H. Gobind Khorana
1970 Discovered reverse transcriptase H. Temin
D. Baltimore
1972 In vitro first recombination of DNA P. Berg
1973 Plasmid to clone DNA H. Boyer
S. Cohen
1976 Development of Southern Blot technique E. Southern
1977 Development of the DNA sequencing technique W. Gilbert
F. Sanger
1983 Development of polymerase chain reaction (PCR) K. Mullis
1990 Development of the Human Genome Project Various research 
groups
1990 Introduction of BLAST, “fast sequence similarity searching tool” S. Karlin 
S.F. Altshul
1991 Introduction of EST, “expressed sequence tag sequencing” J.C. Venter 
et al.
1996 Development of microarrays P. Brown
2001 The announcement of the human genome draft version (3200 Mb) F.S. Collins
J.C. Venter
2002 Final presentation of human genome F.S. Collins
J.C. Venter
























and resolved [33]; once more Hippocrates has paved 
the corrected route for us to follow [1, 4, 31].
Hippocrates teaching is founded on the sacred re-
spect of the patient; this being the necessary prerequi-
site to face and to overcome the huge challenges and 
contradictions of the post genomic medicine [1, 31, 33].
This medical approach aims to maintain the wellness 
status by exploiting the knowledge of genetic maps, 
molecular pathways and health strategies built up by 
the systematic analysis of millions of records, from 
millions of individuals and patients, invited to share 
their personal information. These premises raise many 
ethical challenges that need to be faced [33]. Among 
these, the correct sharing, storage and use of personal 
information are important issues to be met to guaran-
tee the privacy of patients and, therefore, their willing-
ness and acceptance to disclose their own data [29, 
33]. Hippocrates’ oath states “Whatever I may say or 
hear in the course of a treatment, or even unrelated 
to treatment, in regard to the lives of men that should 
not be spoken of abroad, I will keep to myself, holding 
such things in confidence” [34], underlining the physi-
cian’s responsibility of caring and protecting lives and 
feelings of patients. 
Additionally, most of these data will be based on new 
diagnostic approaches derived from the Human Genome 
Project and “omics” technologies. These procedures are 
extremely complex and expensive; therefore, they are not 
easily available and affordable [35, 36] to everyone. 
The high costs could generate a type of “financial 
discrimination” of people who can or cannot undertake 
the most appropriate diagnostic path. This consider-
ation highlights that “omics” approaches could lead to 
an inequitable medicine. Additionally, relevant “omics” 
data could be absent due to this financial aspect could 
generate holes in the computational system, and this 
may compromise the right interpretation of genotypes 
and metabolic pathways [17, 35, 36].
Hence, it would be desirable to add a new “P” to P4 
Medicine, namely, a “P” for “People” Medicine to over-
come any computational bias and social discrimination, 
as Hippocrates had sworn to Apollo “for the benefit of my 
patients and protect them from harm and injustice” [34]. 
Some scientists have already added the “P5” of Psy-
cho-cognitive medicine [37-39] and the “P6” of Public 
and Population-based medicine [40]. The “P5” under-
lines that psycho-cognitive attitudes of each individual 
being unique and relevant for health outcome, as they 
may affect therapeutic choices, influence the physician-
patient relationship and, in the end, determine how in-
dividuals prevent and cope with diseases.
Undoubtedly, the P5 fully accomplishes the Hip-
pocrates’ concept that each individual should be con-
sidered as a unique psychosomatic entity [1-5, 38]. The 
“P6” summarizes the Cumming’s idea, “Healthcare of 
the future thus becomes P4 + Cn where C represents 
community, collaboration, self-caring, co-creation, co-
production, and co-development using technologies 
delivered via the Internet” [41]. This “P6” concept was 
derived from Salvatore Iaconesi’s experience of sharing 
his illness on the public domain, in asking for help and 
consideration. 
In fact, the new proposed “P” of People Medicine 
also includes most of the “C” of Cumming’s idea of P4 
+ Cn, but it tries to go further in avoiding discrimina-
tion. This goal is very difficult to achieve, considering 
that nowadays a large part of the world population does 
not have access to basic health care, and thus it would 
be pure fiction to have “omics” diagnostic and thera-
peutic paths included for this population [35]. 
Medicine should be for People, where wellbeing is 
a legitimate expectation of every person regardless of 
social status. Yet, this appears not to be the case [42, 
43]. Biomedical research requires enormous financial 
resources and its tools cannot be supplied gratis. How-
ever, these should be made more affordable and widely 
available. Individuals should never have to give up the 
hope of benefiting from the best diagnostic and thera-
peutic approaches [43]. 
It needs to be stressed that, as P4 medicine and its 
“omics” protocols are in their infancy, and most of their 
applications still need to be harmonized, they cannot 
always provide what is expected of them. Hence, the 
“omics” approach of P4 Medicine could delude and dis-
appoint patients who have high expectations related to 
the prediction, prevention and cure of diseases [35, 44].
As the “omics” will generate more knowledge on the 
mechanisms of gene regulation, transcription and trans-
lation, as well as proteins interactions, P4 Medicine is 
expected to increasingly pursue effectively its tasks and 
to guarantee a better health outcome. It again needs to 
be stressed that this goal can only be achieved through 
the analysis of huge amounts of “omics” data (genomic, 
transcriptomic, metabolomic, proteomic and so on), 
obtained without any financial bias. Together, these 
unbiased data may provide the right information to im-
prove the knowledge of physiological and pathological 
pathways and to configure the appropriate therapeutic 
strategies. This requires implementing the “P” of People 
Medicine, so that a majority of individuals can be in-
volved and included in “omics” screenings. 
CONCLUSIONS
P4 Medicine and Hippocrates are centuries apart, yet 
their concepts of best therapeutic approaches are very 
similar. P4 Medicine is based on omics techno-science 
and demands patients actively participate in medical 
decisions to guide the necessary changes in fully achiev-
ing their goals. Hippocrates considered the body as a 
unified whole and a unique psychosomatic entity, and 
based his method on the analysis of symptoms and 
how these were affected by natural and social environ-
ments. Additionally, he underlined preventive and pre-
dictive medicine as the best therapeutic approach, and 
strengthened the importance of the alliance between 
physician and patient. Even, in the post genomic era the 
therapeutic alliance is going to be crucial for fulfilling 
the Participation and People requirements and demon-
strating how care of individuals, and consideration for 
their needs are still the first and most important steps to 
accomplishing great achievements. These “Ps” will also 
reinforce the alliance between patient and physician, 
and lead to a “human omics medicine”, which bonds 
together scientific achievements and compassion, and 
























is able to face illness and cope with distress, according 
to Hippocrates ideal “Wherever the art of medicine is 
loved, there is also a love of humanity”. 
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